eXoZymes, Inc. (EXOZ) Financial Ratios
4 years of historical data (2021–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
7.80
↓-39% vs avg
5yr avg: 12.87
30Y Low12.9·High12.9
ROE
↓
-116.8%
↓+37% vs avg
5yr avg: -184.8%
30Y Low-413%·High-101%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
EXOZ Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
eXoZymes, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $84M | $134M | — | — | — |
| Enterprise Value | $76M | $126M | — | — | — |
| P/E Ratio → | -13.89 | — | — | — | — |
| P/S Ratio | — | — | — | — | — |
| P/B Ratio | 7.80 | 12.87 | — | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EXOZ EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
EXOZ Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -116.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| ROE | -116.8% | -116.8% | -412.5% | -108.7% | -101.0% |
| ROA | -70.6% | -70.6% | -65.3% | -55.5% | -51.5% |
| ROIC | -273.9% | -273.9% | -104.3% | -71.6% | — |
| ROCE | -92.4% | -92.4% | -112.5% | -66.7% | -66.5% |
EXOZ Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $10M exceeds total debt of $1M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.13 | — | 0.44 | 0.60 |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.80 | — | 0.04 | 0.14 |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — |
Net cash position: cash ($10M) exceeds total debt ($1M)
EXOZ Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
eXoZymes, Inc.'s current ratio of 8.12x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.32x to 8.12x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Current Ratio | 8.12 | 8.12 | 0.50 | 2.32 | 2.61 |
| Quick Ratio | 8.12 | 8.12 | 0.50 | 2.32 | 2.61 |
| Cash Ratio | 7.29 | 7.29 | 0.03 | 0.88 | 1.37 |
| Asset Turnover | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
EXOZ Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
eXoZymes, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $8M | $8M | $8M | $8M |
Peer Comparison
Compare EXOZ with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 EXOZYou | $84M | -13.9 | — | — | — | — | -116.8% | -273.9% | — |
 GEVO | $493M | -14.5 | 102.1 | — | 30.2% | -11.7% | -7.0% | -2.8% | 25.9 |
 LNZA | $53M | -0.3 | — | — | 47.6% | -219.7% | -215.3% | -147.7% | — |
 MCRB | $74M | 12.1 | — | 86.0 | -423.8% | -11910.1% | 19.6% | -90.3% | — |
 CODX | $2M | -0.1 | — | — | 64.3% | -5025.5% | -125.2% | -73.9% | — |
 NUVB | $2B | -8.0 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
See EXOZ's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EXOZ Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EXOZ vs GEVO
Side-by-side business, growth, and profitability comparison vs Gevo, Inc..
Start ComparisonEXOZ — Frequently Asked Questions
Quick answers to the most common questions about buying EXOZ stock.
What is eXoZymes, Inc.'s P/E ratio?
eXoZymes, Inc.'s current P/E ratio is -13.9x. This places it at the 50th percentile of its historical range.
What is eXoZymes, Inc.'s ROE?
eXoZymes, Inc.'s return on equity (ROE) is -116.8%. The historical average is -184.8%.
Is EXOZ stock overvalued?
Based on historical data, eXoZymes, Inc. is trading at a P/E of -13.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.